The company received a notice of allowance from the U.S. Patent and Trademark Office for Exparel’s chemical composition, according to a news release. Pacira plans to submit the patent for listing in the FDA Approved Drug Products with Therapeutic Equivalence Evaluations.
Pacira also received a notice of allowance from the USPTO for a patent relating to a novel manufacturing process for Exparel.
Both patents will have an expiration date of Jan. 22, 2041.
